Communications Medicine (Nov 2022)

Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

  • Mary Kathryn Dahlgren,
  • Ashley M. Lambros,
  • Rosemary T. Smith,
  • Kelly A. Sagar,
  • Celine El-Abboud,
  • Staci A. Gruber

DOI
https://doi.org/10.1038/s43856-022-00202-8
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 10

Abstract

Read online

Dahlgren et al. conduct an open-label phase 2 trial of a full-spectrum, high-cannabidiol product in 14 patients with moderate-to-severe anxiety. Anxiety is significantly reduced and the drug well-tolerated with no serious adverse events.